Innovative Ultrasound Technology in Neuromuscular Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Amyotrophic Lateral Sclerosis
- Sponsor
- Beth Israel Deaconess Medical Center
- Enrollment
- 223
- Locations
- 1
- Primary Endpoint
- Quantitative ultrasound data, including quantified grayscale data and backscattered acoustic data
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.
Investigators
Seward Rutkove
Professor of Neurology
Beth Israel Deaconess Medical Center
Eligibility Criteria
Inclusion Criteria
- •History of a well-defined, localized or generalized neuromuscular condition producing weakness or muscle atrophy, including disuse atrophy.
Exclusion Criteria
- •Multiple generalized neuromuscular conditions.
Outcomes
Primary Outcomes
Quantitative ultrasound data, including quantified grayscale data and backscattered acoustic data
Time Frame: 1 year
Ultrasound data will be collected on multiple muscles in each person. The images will then be quantified using either 1. A grayscale technique in which the images themselves are analyzed via standard image software (e.g., Adobe Photoshop) as to level of echo intensity in a pre-specific region of interest or 2. the raw quantified backscatter data is captured by the transducer, expressed as a unit of power, in the same pre-specified area of interest